Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC) (PHPC-02)

Genetic Immunity

Status: Completed

Conditions: HIV Infection

Treatments: Biological: Placebo; Drug: HAART; Biological: DermaVir

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00918840

2008-003765-11 (EudraCT Number)

PHPC-02

Details and patient eligibility

About

PHPC-02 is a phase II, randomized, placebo-controlled trial designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces elevations of HIV-specific T cell precursors with high proliferative capacity (PHPC) in HIV-1-infected individuals, and whether the quantity of PHPC correlates with the viral load set point following analytical treatment interruption (ATI). Subjects will be randomized to receive either DermaVir Patch (8 subjects per cohort) or DermaVir Patch Placebo (8 subjects per cohort) every four weeks for three applications while receiving maximally suppressive HAART. HAART will be discontinued at Week 9 for an ATI period of 20 weeks.

Full description

16 subjects on maximally suppressive HAART were randomized to receive three doses of either DermaVir or Placebo immunotherapy.

Subjects receive three DermaVir/Placebo treatments over eight weeks (Weeks 0, 4 and 8) while receiving HAART. HAART is discontinued for a 20 week ATI.

Resumption of HAART during ATI is subjects experience:

• A confirmed CD4+ cell decrease by > 50%
• A confirmed CD4+ cell decrease to less than 350 counts/mL
• A confirmed VL increase > 300,000 copies
• Emergence of CDC AIDS related event(s)
• Signs or symptoms of clinically significant immunosuppression
• The subject or the subject's clinician wishes to restart HAART
• The subject becomes pregnant

Enrollment: 16 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Main inclusion Criteria:

• HIV-1 infection
• On a non-hydroxyurea based HAART for at least one year
• Pre-HAART CD4 nadir > 250 cells/mm3
• Pre-HAART viral load > 5,000 copies/mL
• Undetectable viral load for the six month period preceding the study
• CD4 T-cell count >500 cells/mm3 for the six month period preceding the study

Main exclusion Criteria:

• No skin disease
• No hypersensitivity to adhesive tape or Tegaderm
• No history of keloid
• No history of vitiligo, melasma, skin cancer
• No tattoos or changes in pigment at the skin treatment sites
• No autoimmune diseases
• No hepatitis B, C coinfections

Trial design

16 participants in 2 patient groups

DermaVir + HAART

Description:

* Dosage: 0.4 mg DNA * Dosage form: 3.2 mL DNA/PEIm nanomedicine * Administration with 4 DermaPrep patches * Frequency: every 4 weeks * Duration: 8 weeks (3 DermaVir treatments)

Treatment:

Biological: DermaVir

Drug: HAART

Placebo + HAART

Description:

* Dosage form: 3.2 mL Placebo * Administration with 4 DermaPrep patches * Frequency: every four weeks * Duration: 8 weeks (3 Placebo treatments)

Treatment:

Drug: HAART

Biological: Placebo